News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Juvaris BioTherapeutics Announces License to Colby Pharmaceutical for JVRS-100 and CLDC (Cationic Lipid-DNA Complex) Platform for Human Health


9/9/2011 10:40:05 AM

BURLINGAME, Calif.--(BUSINESS WIRE)--Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvants, adjuvanted vaccines and immunotherapeutics for infectious diseases and cancer, today announced it has entered into an exclusive license agreement with Colby Pharmaceutical Company for the worldwide development and commercialization of Juvaris’ Cationic Lipid-DNA Complex (CLDC) technology and JVRS-100 product candidate, including its intellectual property estate and human clinical development programs, in the field of human (non-animal) health.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES